Details of the Drug

General Information of Drug (ID: DMHPYSM)

Drug Name
Ellipticine
Synonyms
ellipticine; 519-23-3; Elliptisine; 5,11-Dimethyl-6H-pyrido[4,3-b]carbazole; NSC 71795; TCMDC-125546; NSC-71795; 5,11-Dimethyl-6H-pyrido(4,3-b)carbazole; ICIG 770; 5,11-Dimethylpyrido[4,3-b]carbazole; CCRIS 2003; CP 5; UNII-117VLW7484; NSC71795; EINECS 208-264-0; CHEMBL123; BRN 0221300; MLS000736786; MLS000028487; CHEBI:4776; 6H-Pyrido(4,3-b)carbazole, 5,11-dimethyl-; CCG-36483; 117VLW7484; SMR000058370; 6H-Pyrido[4,3-b]carbazole,5,11-dimethyl-; 6H-Pyrido[4,3-b]carbazole, 5,11-dimethyl-; SR-01000003083; elliptecine; Ellipticin
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 246.31
Logarithm of the Partition Coefficient (xlogp) 4.8
Rotatable Bond Count (rotbonds) 0
Hydrogen Bond Donor Count (hbonddonor) 1
Hydrogen Bond Acceptor Count (hbondacc) 1
Chemical Identifiers
Formula
C17H14N2
IUPAC Name
5,11-dimethyl-6H-pyrido[4,3-b]carbazole
Canonical SMILES
CC1=C2C=CN=CC2=C(C3=C1NC4=CC=CC=C43)C
InChI
InChI=1S/C17H14N2/c1-10-14-9-18-8-7-12(14)11(2)17-16(10)13-5-3-4-6-15(13)19-17/h3-9,19H,1-2H3
InChIKey
CTSPAMFJBXKSOY-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
3213
ChEBI ID
CHEMBL123
CAS Number
519-23-3
UNII
117VLW7484
DrugBank ID
DB17026
TTD ID
D00DNY
Drug-Molecule Activity Atlas (DMA)NEW Click to Jump to the Detailed DMA Information of This Drug
Drug Pharmacogenomic Perturbation (DPP)NEW Click to Jump to the Detailed DPP Information of This Drug
Drug ADMET Endpoint Profile (DAE)NEW Click to Jump to the Detailed DAE Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
DNA topoisomerase II (TOP2) TT0IHXV TOP2A_HUMAN ; TOP2B_HUMAN Inhibitor [1]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
Cyclin-dependent kinase inhibitor 1 (CDKN1A) OTQWHCZE CDN1A_HUMAN Gene/Protein Processing [2]
Cyclin-dependent kinase inhibitor 1B (CDKN1B) OTNY5LLZ CDN1B_HUMAN Gene/Protein Processing [3]
Cytochrome P450 2C19 (CYP2C19) OTFMJYYE CP2CJ_HUMAN Regulation of Drug Effects [4]
E3 ubiquitin-protein ligase XIAP OT24GP9B XIAP_HUMAN Gene/Protein Processing [5]
Histone H2AX (H2AX) OT18UX57 H2AX_HUMAN Gene/Protein Processing [6]
M-phase inducer phosphatase 3 (CDC25C) OTPQI71S MPIP3_HUMAN Gene/Protein Processing [5]
Mitogen-activated protein kinase 1 (MAPK1) OTH85PI5 MK01_HUMAN Post-Translational Modifications [3]
Mitogen-activated protein kinase 3 (MAPK3) OTCYKGKO MK03_HUMAN Post-Translational Modifications [3]
Poly polymerase 1 (PARP1) OT310QSG PARP1_HUMAN Protein Interaction/Cellular Processes [3]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

References

1 In vitro sensitivity of Trichomonas vaginalis to DNA topoisomerase II inhibitors. Southeast Asian J Trop Med Public Health. 2000 Mar;31(1):118-22.
2 The impact of chemotherapeutic drugs on the CYP1A1-catalysed metabolism of the environmental carcinogen benzo[a]pyrene: effects in human colorectal HCT116 TP53(+/+), TP53(+/-) and TP53(-/-) cells. Toxicology. 2018 Apr 1;398-399:1-12.
3 Ellipticine induces apoptosis in human endometrial cancer cells: the potential involvement of reactive oxygen species and mitogen-activated protein kinases. Toxicology. 2011 Nov 18;289(2-3):91-102. doi: 10.1016/j.tox.2011.07.014. Epub 2011 Aug 6.
4 Ellipticine oxidation and DNA adduct formation in human hepatocytes is catalyzed by human cytochromes P450 and enhanced by cytochrome b5. Toxicology. 2012 Dec 16;302(2-3):233-41. doi: 10.1016/j.tox.2012.08.004. Epub 2012 Aug 16.
5 The anti-proliferative inhibition of ellipticine in human breast mda-mb-231 cancer cells is through cell cycle arrest and apoptosis induction. Anticancer Drugs. 2005 Aug;16(7):789-95. doi: 10.1097/01.cad.0000171768.36317.93.
6 Ellipticine-loaded apoferritin nanocarrier retains DNA adduct-based cytochrome P450-facilitated toxicity in neuroblastoma cells. Toxicology. 2019 May 1;419:40-54. doi: 10.1016/j.tox.2019.03.009. Epub 2019 Mar 23.